447 related articles for article (PubMed ID: 23357603)
1. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
[TBL] [Abstract][Full Text] [Related]
2. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
4. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
5. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
6. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
7. Regenerative effects of umbilical cord matrix cells (UCMCs) in a rodent model of rotenone neurotoxicity.
Salama M; ElDakroory SAE; ElTantawy D; Ghanem AA; Elghaffar HA; Elhusseiny M; ElHak SG
Environ Toxicol Pharmacol; 2012 Sep; 34(2):338-344. PubMed ID: 22717662
[TBL] [Abstract][Full Text] [Related]
8. Noscapine Prevents Rotenone-Induced Neurotoxicity: Involvement of Oxidative Stress, Neuroinflammation and Autophagy Pathways.
Jayaraj RL; Beiram R; Azimullah S; M F NM; Ojha SK; Adem A; Jalal FY
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361780
[TBL] [Abstract][Full Text] [Related]
9. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
10. Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-L-carnitine.
Sarkar S; Gough B; Raymick J; Beaudoin MA; Ali SF; Virmani A; Binienda ZK
Neurosci Lett; 2015 Oct; 606():53-9. PubMed ID: 26321151
[TBL] [Abstract][Full Text] [Related]
11. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
13. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
14. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
16. Selective A
Fathalla AM; Soliman AM; Moustafa AA
Neurosci Lett; 2017 Mar; 643():89-96. PubMed ID: 28213070
[TBL] [Abstract][Full Text] [Related]
17. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
Thomas Tayra J; Kameda M; Yasuhara T; Agari T; Kadota T; Wang F; Kikuchi Y; Liang H; Shinko A; Wakamori T; Vcelar B; Weik R; Date I
Brain Res; 2013 Mar; 1502():55-70. PubMed ID: 23380533
[TBL] [Abstract][Full Text] [Related]
18. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
19. Valeric Acid Protects Dopaminergic Neurons by Suppressing Oxidative Stress, Neuroinflammation and Modulating Autophagy Pathways.
Jayaraj RL; Beiram R; Azimullah S; Mf NM; Ojha SK; Adem A; Jalal FY
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081327
[TBL] [Abstract][Full Text] [Related]
20. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
